Delving into the Latest Updates on Apollo Therapeutics with Synapse

Overview

Tags

Neoplasms

Digestive System Disorders

Urogenital Diseases

Small molecule drug

Monoclonal antibody

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	5
Hemic and Lymphatic Diseases	2
Immune System Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	4
Monoclonal antibody	2
Prophylactic vaccine	1
Chemical drugs	1

Top 5 Target	Count

CK2(Casein kinase II)	1
SLC39A12(solute carrier family 39 member 12)	1
IL-18(Interleukin 18)	1
PERK(eukaryotic translation initiation factor 2 alpha kinase 3)	1
EIF2AK4(eukaryotic translation initiation factor 2 alpha kinase 4)	1

The AP13CP02 study is a phase 2, open-label, dose escalation trial to determine how safe and tolerable multiple subcutaneous (SC) injections of APL-9796 are for patients with PH. The study will also assess how effective APL-9796 could be for treating patients with PH and whether the body produces antibodies working against APL-9796.
The trial will be conducted in two parts:
* Part A: Up to 36 adults with WHO Group 1 Pulmonary arterial hypertension (PAH).
* Part B (optional): Up to 12 adults with WHO Group 3 - PH associated with ILD (PH-ILD).

Start Date09 Apr 2025

Sponsor / Collaborator

Apollo Therapeutics

NCT06399757

/ RecruitingPhase 1/2

A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors

This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).

Start Date18 Jun 2024

Sponsor / Collaborator

Apollo Therapeutics

NCT06372717

/ RecruitingPhase 1/2

A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-4098 Alone and/or in Combination With Azacitidine in Adults With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome/AML (MDS/AML) or Myelodysplastic Syndrome With Excess Blasts (MDS-EB)

This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-4098 alone and/or in combination with azacitidine for the treatment of relapsed or refractory (R/R) acute myeloid leukemia (AML), myelodysplastic syndrome (MDS)/AML and MDS-excess blasts (EB). Participants with the MDS-EB subtype will be eligible for the Phase 1 part of the study only.

Start Date04 Jun 2024

Sponsor / Collaborator

Apollo Therapeutics

100 Clinical Results associated with Apollo Therapeutics

Login to view more data

0 Patents (Medical) associated with Apollo Therapeutics

Login to view more data

1

Literatures (Medical) associated with Apollo Therapeutics

21 Apr 2025·Cancer Research

Abstract 1726: Preclinical development of APL-045: A selective PERK inhibitor targeting ER stress pathways in cancer

Author: Stead, Clara ; Demont, Emmanuel ; Kolluri, Krishna ; Glossop, Paul ; Clemo, Nadine ; Butt, Richard ; Wright, Susanne

AbstractThe unfolded protein response (UPR) is a critical component of the integrated stress response (ISR) pathway, activated in response to the accumulation of unfolded or misfolded proteins within the endoplasmic reticulum (ER). A key mediator in this pathway is protein kinase RNA-like ER kinase (PERK), which becomes active under conditions of ER stress. Upon activation, PERK phosphorylates eIF2α, temporarily halting general protein translation to reduce the burden on the ER. Cancer cells can exploit PERK signalling to enhance their survival and proliferation under stress, leveraging this pathway to adapt to UPR triggered by hypoxic, nutrient-deprived tumour microenvironments, or as a response to anticancer therapies. Inhibition of PERK is therefore a promising therapeutic target in oncology.APL-045 is a novel, selective, ATP-competitive inhibitor of PERK. APL-045 demonstrated potent inhibition of PERK, with a Ki of 4.6 nM and IC50 for eIF2α phosphorylation inhibition of 20 nM. Selectivity screening showed high specificity, with very limited off-target effects among 468 kinases tested in a Kinome Scan®.In vitro studies demonstrated that APL-045 effectively inhibited downstream effectors of the PERK-mediated UPR pathway, ATF4 and CHOP, in a dose-dependent manner with the IC50 values ranged from 50 to 250 nM across renal cell carcinoma (RCC) and colorectal cancer cell lines. In vivo, APL-045 significantly reduced tumour volume in 786-O RCC xenograft models, achieving over 95% tumour growth inhibition after three weeks of treatment. These findings underscore the potential of APL-045 as a promising therapeutic candidate for cancers driven by PERK-dependent pathways.APL-045 has a highly favourable pharmacokinetic profile, with good solubility, high permeability, and robust metabolic stability in both microsomal and hepatic assays in rodent, dog and human in vitro systems. These properties have translated to high bioavailability. This favourable profile is projected to represent a best-in-class PERK inhibitor.These data describe the efficacy and drug-like properties of APL-045, a candidate stage, best-in-class PERK inhibitor poised to progress into IND-enabling and clinical studies.Citation Format:Krishna Kolluri, Clara Stead, Susanne Wright, Paul Glossop, Emmanuel Demont, Richard Butt, Nadine Clemo. Preclinical development of APL-045: A selective PERK inhibitor targeting ER stress pathways in cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1726.

100 Deals associated with Apollo Therapeutics

Login to view more data

100 Translational Medicine associated with Apollo Therapeutics

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 10 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

Phase 2 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

APL-4098	Relapsing acute myeloid leukemia More	Phase 2 Clinical
APL-5125	uterus adenocarcinoma More	Phase 2 Clinical
APL-9796 ( SLC39A12 )	Pulmonary Arterial Hypertension More	Phase 2
Camoteskimab ( IL-18 )	Dermatitis, Atopic More	Phase 2
APL-045 ( PERK )	Renal Cell Carcinoma More	Preclinical